A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC
Investigator(s):
Steven M. Dubinett, M.D.;
Organization:
UCLA
NCT Number:
Disease Name:
Lung Cancer
Disease Category:
Trial Phases:
Phase 1
Trial Status:
Recruiting

Steven M. Dubinett, M.D.
Trial Contact:
Lia Etheridge
(310) 825-7174
letheridge@mednet.ucla.edu